• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Applied Dna Scns (NQ: APDN )

    0.1867 -0.0096 (-4.89%)
    Streaming Delayed Price Updated: 1:37 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Applied Dna Scns

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    We are starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to read about this morning! 
    Via InvestorPlace
    Applied DNA Announces 1-For-20 Reverse Stock Split
    Via ACCESSWIRE
    The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
    Analysts rate the stocks, but who rates the analysts? This is a look at five of the highest-rated analysts tracked by Marketbeat.com based on 12-month ROI. 
    Via MarketBeat
    Topics Cannabis
    Exposures Cannabis
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Recap: Applied DNA Sciences Q1 Earnings
    Via Benzinga
    Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start
    Via ACCESSWIRE
    Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress
    Via ACCESSWIRE
    Earnings Scheduled For February 8, 2024
    Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
    Via Benzinga
    Earnings Preview For Applied DNA Sciences
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Applied DNA Sciences: Q4 Earnings Insights
    Via Benzinga
    Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results
    Via ACCESSWIRE
    Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)
    Via ACCESSWIRE
    Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
    Via ACCESSWIRE
    Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform
    Via ACCESSWIRE
    Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
    Via ACCESSWIRE
    Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    APDN Stock Earnings: Applied DNA Sciences Beats EPS, Misses Revenue for Q4 2023
    APDN stock results show that Applied DNA Sciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    Earnings Scheduled For December 7, 2023
    Companies Reporting Before The Bell • IES Hldgs (NASDAQ:IESC) is expected to report earnings for its fourth quarter. 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
    Via ACCESSWIRE
    Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
    Via ACCESSWIRE
    Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals
    Via ACCESSWIRE
    Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs
    Via ACCESSWIRE
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.